Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213522 | 0.95 | THRB (0.90) | THRBTHRA | |
| SCHEMBL6216237 | 0.89 | THRB (0.81) | THRBTHRA | |
| SCHEMBL6213056 | 0.89 | THRB (1.00) | THRBTHRA | |
| SCHEMBL6216224 | 0.89 | THRB (0.80) | THRBTHRA | |
| SCHEMBL6213947 | 0.88 | THRB (0.79) | THRBTHRA | |
| SCHEMBL6286787 | 0.85 | THRB (0.75) | THRBTHRA | |
| SCHEMBL6217508 | 0.84 | THRB (0.72) | THRBTHRA | |
| SCHEMBL6215547 | 0.81 | THRB (0.73) | THRBTHRA | |
| SCHEMBL6217453 | 0.80 | THRB (0.71) | THRBTHRA | |
| SCHEMBL6215414 | 0.80 | THRB (0.79) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098303-A1 | Method of promoting nail growth using thyromimetic compounds | DOHERTY NIALL S | 2011-04-28 | — | — | US | claimed |
| US-20080125433-A1 | Method of treating hair loss using thyromimetic compounds | CORNELIUS PETER | 2008-05-29 | — | — | US | claimed |
| EP-1262177-B1 | Medical use of thyromimetic compounds to treat hair loss and compositions | PFIZER PROD INC (US) | 2006-08-23 | — | — | EP | claimed |
| US-6930107-B2 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-16 | — | — | US | claimed |
| EP-1088819-B1 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004047827-A1 | METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-20030007941-A1 | Method of treating hair loss using thyromimetic compounds | CORNELIUS PETER (US) | 2003-01-09 | — | — | US | claimed |
| EP-1262177-A2 | Medical use of thyromimetic compounds to treat hair loss and compositions | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| US-20170056307-A1 | EPROTIROME FOR USE IN THE PREVENTION AND/OR TREATMENT OF HAIR DISORDERS AND COMPOSITIONS THEREOF | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20150182482-A1 | EPROTIROME FOR USE IN THE PREVENTION AND/OR TREATMENT OF HAIR DISORDERS AND COMPOSITIONS THEREOF | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-07-02 | — | — | US | disclosed |
| EP-2695611-B1 | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof | WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR (DE) | 2014-10-01 | — | — | EP | disclosed |
| WO-2014023698-A1 | EPROTIROME FOR USE IN THE PREVENTION AND/OR TREATMENT OF HAIR DISORDERS AND COMPOSITIONS THEREOF | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTTEL (DE) | 2014-02-13 | — | — | WO | disclosed |
| EP-2695611-A1 | Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof | Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) | 2014-02-12 | — | — | EP | disclosed |
| US-20110098303-A1 | Method of promoting nail growth using thyromimetic compounds | DOHERTY NIALL S | 2011-04-28 | — | — | US | disclosed |
| US-6787652-B1 | LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES | PFIZER, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | DOW ROBERT L (US) | 2004-08-12 | — | — | US | disclosed |
| WO-2004047827-A1 | METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20030007941-A1 | Method of treating hair loss using thyromimetic compounds | CORNELIUS PETER (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1262177-A2 | Medical use of thyromimetic compounds to treat hair loss and compositions | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182482-A1 | EPROTIROME FOR USE IN THE PREVENTION AND/OR TREATMENT OF HAIR DISORDERS AND COMPOSITIONS THEREOF | PNMT, COXFA4L2, ERLIN1 | THRB 1673/4885THRA 1079/4885 |
| US-20080125433-A1 | Method of treating hair loss using thyromimetic compounds | TRHDE, TPO, THRB | THRB 3/4885THRA 4/4885 |
| US-20170056307-A1 | EPROTIROME FOR USE IN THE PREVENTION AND/OR TREATMENT OF HAIR DISORDERS AND COMPOSITIONS THEREOF | PNMT, COXFA4L2, ERLIN1 | THRB 1673/4885THRA 1079/4885 |
| US-20030007941-A1 | Method of treating hair loss using thyromimetic compounds | TRHDE, TPO, THRB | THRB 3/4885THRA 4/4885 |
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885 |
| US-20110098303-A1 | Method of promoting nail growth using thyromimetic compounds | TPO, POLR1C, TYR | THRB 29/4885THRA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.